


Data Sheet

Product Name:	Vafidemstat
Cat. No.:	CS-0058593
CAS No.:	1357362-02-7
Molecular Formula:	C ₁₉ H ₂₀ N ₄ O ₂
Molecular Weight:	336.39
Target:	Histone Demethylase; Monoamine Oxidase
Pathway:	Epigenetics; Neuronal Signaling
Solubility:	DMSO : 50 mg/mL (ultrasonic)



BIOLOGICAL ACTIVITY:

Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (**LSD1**)/**MAO-B** inhibitor^[1]. IC₅₀ & Target: LSD1/MAO-B^[1] *In Vitro*: Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit^[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease^[2].

References:

[1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases

[2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.

CAIndexNames:

1,3,4-Oxadiazole-2-methanamine,5-amino-N-[(1R,2S)-2-[4-(phenylmethoxy)phenyl]cyclopropyl]-

SMILES:

NC1=NN=C(O1)CN[C@H]2[C@H](C3=CC=C(OCC4=CC=CC=C4)C=C3)C2

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA